These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 20574455)

  • 1. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.
    Chen Y; Peng C; Sullivan C; Li D; Li S
    Leukemia; 2010 Sep; 24(9):1545-54. PubMed ID: 20574455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy of chronic myeloid leukemia.
    Sullivan C; Peng C; Chen Y; Li D; Li S
    Biochem Pharmacol; 2010 Sep; 80(5):584-91. PubMed ID: 20470758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemia Stem Cells in Chronic Myeloid Leukemia.
    Shan Y; DeSouza N; Qiu Q; Li S
    Adv Exp Med Biol; 2019; 1143():191-215. PubMed ID: 31338821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia.
    Chen Y; Li D; Li S
    Cell Cycle; 2009 Nov; 8(21):3488-92. PubMed ID: 19823023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
    Hu Y; Chen Y; Douglas L; Li S
    Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
    J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of Chronic Myeloid Leukemia in Mice.
    Zhang H; Li S
    Methods Mol Biol; 2016; 1465():17-25. PubMed ID: 27581135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
    Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
    Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
    Jin B; Wang C; Li J; Du X; Ding K; Pan J
    Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells.
    Zhang H; Li S
    Protein Cell; 2013 Mar; 4(3):186-96. PubMed ID: 23483480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia.
    Chen Y; Peng C; Sullivan C; Li D; Li S
    Anticancer Agents Med Chem; 2010 Feb; 10(2):111-5. PubMed ID: 20184539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.
    Jin Y; Yao Y; Chen L; Zhu X; Jin B; Shen Y; Li J; Du X; Lu Y; Jiang S; Pan J
    Theranostics; 2016; 6(11):1947-62. PubMed ID: 27570562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myeloid leukemia stem cells.
    Kavalerchik E; Goff D; Jamieson CH
    J Clin Oncol; 2008 Jun; 26(17):2911-5. PubMed ID: 18539972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia.
    Stefanachi A; Leonetti F; Nicolotti O; Catto M; Pisani L; Cellamare S; Altomare C; Carotti A
    Curr Cancer Drug Targets; 2012 Jun; 12(5):571-96. PubMed ID: 22414010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
    Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C
    Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemia stem cells: the root of chronic myeloid leukemia.
    Zhou H; Xu R
    Protein Cell; 2015 Jun; 6(6):403-12. PubMed ID: 25749979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.